Intermittent Senolytic Plus JAK Inhibition Mitigates Off-Target Chromatin Remodeling While Enhancing Senescent Cell Clearance
Hypothesis
Intermittent dosing of dasatinib + quercetin (D+Q) combined with a low‑dose JAK1/2 inhibitor reduces senescent cell burden without inducing senescence‑like chromatin changes in non‑target tissues.
Rationale
Recent work shows that repeated D+Q courses can provoke senescence‑like chromatin alterations even in young cells, raising safety concerns for chronic use [6]. Conversely, JAK‑STAT signaling is a core driver of the SASP, and JAK inhibition attenuates SASP‑mediated inflammation without directly killing senescent cells [2][5]. By pairing intermittent senolysis with transient JAK blockade, we hypothesize that the senolytic pulse clears p16^high^ cells while the JAK inhibitor suppresses residual SASP from any surviving senescent cells, thereby preventing the paracrine induction of chromatin changes in neighboring cells.
Predictions
- In diabetic kidney disease mouse models, intermittent D+Q (3 days on/4 days off) plus low‑dose ruxolitinib will lower renal p16^Ink4a^ and p21^Cip1^ mRNA levels to a greater extent than D+Q alone [2][3].
- The combination will not increase H3K9me3 or DNMT3A expression in cortical tubular cells, markers associated with off‑target chromatin remodeling [6].
- SASP cytokines (IL‑6, IL‑1α, MMP‑9) in serum and kidney homogenates will be significantly reduced relative to D+Q monotherapy, reflecting both senescent cell removal and SASP suppression [2][5].
- Functional readouts (glomerular filtration rate, albuminuria) will improve comparably to D+Q alone, demonstrating that efficacy is not sacrificed.
Experimental Design
- Groups (n=10 per group): vehicle, intermittent D+Q alone, low‑dose ruxolitinib alone, intermittent D+Q + ruxolitinib.
- Duration: 8 weeks, with D+Q administered on days 1‑3 of each week; ruxolitinib given daily at 5 mg/kg (dose shown to inhibit JAK signaling without hematopoietic toxicity).
- Endpoints: qPCR for p16^Ink4a^ and p21^Cip1^, Western blot for H3K9me3 and DNMT3A, ELISA for SASP factors, in vivo renal function assays, histology for SA‑β‑gal.
- Statistical analysis: One‑way ANOVA with Tukey post‑hoc; significance set at p<0.05.
Falsifiability
If the combination does not achieve a greater reduction in senescent markers than D+Q alone, or if H3K9me3/DNMT3A levels rise indicating chromatin disruption, the hypothesis is falsified. Conversely, a clear improvement in both senescent burden and chromatin integrity would support the mechanistic synergy between intermittent senolysis and JAK‑mediated SASP dampening.